Table 1.

Baseline demographic and clinical characteristics and surveillance PSA metrics of study participants in all patients and by reclassification status.

Variable	All patients		No reclassification		Reclassification		P
	No.	%	No.	%	No.	%
No. of patients	191	100	159	100	32	100
Age (years)	64 (57–69)		63 (57–69)		65.5 (59.5–70)		0.18
Race or ethnicity (n = 190)							0.36
White	155	81.6	131	84.5	24	15.5
Black	17	8.9	15	88.2	2	11.8
Hispanic	15	7.9	11	73.3	4	26.7
Asian	3	1.6	2	66.7	1	33.3
Body mass index	29.1 (26.1–31.8)		29.2 (26.2–31.8)		27.9 (25.1–32.6)		0.5
PSA level (ng/mL)
PSA	3.3 ( 2.2–4.3)		3.3 (2.1–4.4)		3 (2.4–4.2)		0.68
PSA density	0.1 (0.1–0.1)		0.1 (0.1–0.1)		0.1 (0.1–0.1)		0.67
PSA velocity (n = 124)	0.1 (−0.1–0.6)		0.1 (−0.2–0.5)		0.4 (0–0.7)		0.04
PSA doubling time (n = 124)	3.4 (−3.4–7.2)		2.7 (−4–7.1)		4.5 (1.4–7.7)		0.34
Testosterone (ng/dL)	379 (295–479)		379 (290–469)		389 (323–494)		0.44
Transrectal ultrasound, total (mL)	43.9 (29.7–56.3)		44 (29.5–57.5)		43.5 (33.6–53.2)		0.81
Gleason score							1.00
5*	1	0.5	1	100	—	—
6	189	99	157	83.1	32	16.9
7	1	0.5	1	100	—	—
Clinical stage							0.86
cT1a*	5	2.6	4	80	1	20
cT1c	164	85.9	137	83.5	27	16.5
cT2a	20	10.5	16	80	4	20
cT2b	1	0.5	1	100	—	—
cT2c	1	0.5	1	100	—	—
Number of surveillance biopsies (n = 183)							<.0001
0	33	18	33	100	—	—
1	72	39.3	62	86.1	10	13.9
2	44	24	37	84.1	7	15.9
3	25	13.7	17	68	8	32
4	8	4.4	2	25	6	75
5	1	0.5	—	—	1	100
Tumor length (mm) (n = 185)							0.03
< 0.5	10	5.4	8	80	2	20
0.5–< 1	84	45.4	77	91.7	7	8.3
1–< 2	68	36.8	52	76.5	16	23.5
2–< 3	23	12.4	17	73.9	6	26.1
5-alpha-reductase inhibitor: current or history of treatment							0.3
No	159	83.2	130	81.8	29	18.2
Yes	32	16.8	29	90.6	3	9.4
Family history, first degree (n = 190)							0.66
No	139	73.2	114	82	25	18
Yes	51	26.8	44	86.3	7	13.7
Family history, second degree (n = 190)							0.29
No	161	84.3	136	84.5	25	15.5
Yes	30	15.7	23	76.7	7	23.3